{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:06:42Z","timestamp":1775488002014,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"BT"},{"name":"BT"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.toxicon.2019.12.005","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T21:21:58Z","timestamp":1575667318000},"page":"64-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Therapeutically relevant features of botulinum toxin drugs"],"prefix":"10.1016","volume":"175","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.toxicon.2019.12.005_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: long term results","volume":"16","author":"Dressler","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2019.12.005_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","article-title":"Five-year experience with incobotulinumtoxinA (Xeomin\u00ae): the first botulinum toxin drug free of complexing proteins","volume":"19","author":"Dressler","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2019.12.005_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40734-017-0049-z","article-title":"Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum toxin therapy","volume":"4","author":"Dressler","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"issue":"Suppl. l","key":"10.1016\/j.toxicon.2019.12.005_bib4","first-page":"S23","article-title":"Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): identical potency labeling in the hemidiaphragm assay","volume":"123","author":"Dressler","year":"2016","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2019.12.005_bib5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00702-017-1767-y","article-title":"Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?","volume":"124","author":"Dressler","year":"2017","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2019.12.005_bib6","series-title":"Treatment of Dystonia","article-title":"Pharmacology of botulinum toxins","author":"Dressler","year":"2018"},{"issue":"Suppl. 1","key":"10.1016\/j.toxicon.2019.12.005_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of Botox, Dysport and myobloc\/NeuroBloc","volume":"13","author":"Dressler","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2019.12.005_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","article-title":"Measuring the potency labelling of onabotulinumtoxinA (Botox\u00ae) and Xeomin\u00ae in an LD50 assay","volume":"119","author":"Dressler","year":"2012","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2019.12.005_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","article-title":"Botulinum toxin therapy of cervical dystonia: comparing Botox\u00ae and Xeomin\u00ae","volume":"121","author":"Dressler","year":"2014","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2019.12.005_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00702-016-1522-9","article-title":"Botulinum toxin therapy: reduction of injection site pain by pH normalisation","volume":"123","author":"Dressler","year":"2016","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2019.12.005_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00702-018-1897-x","article-title":"Comparing incobotulinumtoxinA (Xeomin\u00ae) and onabotulinumtoxinA (Botox\u00ae): identical potency labelling in the hemidiaphragm assay","volume":"125","author":"Dressler","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2019.12.005_bib12","series-title":"Botulinum Toxin Type A for Injection","first-page":"1327","year":"2008"},{"key":"10.1016\/j.toxicon.2019.12.005_bib13","first-page":"571","volume":"vol. 5","year":"2008"},{"key":"10.1016\/j.toxicon.2019.12.005_bib14","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs - a help or hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"10.1016\/j.toxicon.2019.12.005_bib15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2019.12.005_bib16","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","article-title":"Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin","volume":"151","author":"Lee","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.toxicon.2019.12.005_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","article-title":"Dose standardisation of botulinum toxin","volume":"59","author":"Marion","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2019.12.005_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0000000000000101","article-title":"A comparison of Botox 100 U\/mL and Dysport 100 U\/mL using dose conversion ratio 1: 3 and 1: 1.7 in the treatment of cervical dystonia: a double-blind, randomized, crossover trial","volume":"38","author":"Rystedt","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2019.12.005_bib19","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.3390\/toxins8030065","article-title":"Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010119307615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010119307615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:13:36Z","timestamp":1758575616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010119307615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":19,"alternative-id":["S0041010119307615"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2019.12.005","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutically relevant features of botulinum toxin drugs","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}